:: Volume 14, Issue 1 (Winter 2023) ::
Caspian J Intern Med 2023, 14(1): 89-93 Back to browse issues page
Disease Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
Negar Molazadeh , Mohammad ali Sahraian , Mahsa Ghajarzadeh
Universal Council of Epidemiology (UCE), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran , m.ghajarzadeh@gmail.com
Abstract:   (1525 Views)
Background: Medication satisfaction is a patient-reported outcome which could show medication adherence. The aim of this study was to determine Iranian MS patients’ satisfaction with Disease Modifying Therapies (DMTs).
Methods: A standardized questionnaire was developed using Treatment Satisfaction Questionnaire for Medication (TSQM). The online link was released on IMSS (Iranian Multiple Sclerosis Society) social media channel, accessible to 4272 MS patients totally.
Results: Three hundred and ninety-four patients participated in our survey with 324 females, 70 males and an F/M ratio of 4.6:1. The most frequent DMTs used were interferon-beta (IFNβ) followed by rituximab. The mean effectiveness and global satisfaction scores were significantly higher for injectable DMTs, while the convenience score was significantly higher for oral DMTs. Mean effectiveness and side-effect scores were significantly higher in the Tysabri group and convenience score was significantly higher in the fingolimod group while global satisfaction was higher in the IFNβ group.
Conclusion: The global satisfaction and effectiveness were significantly higher with injectable DMTs while the convenience score was significantly higher with oral DMTs.
Keywords: Multiple sclerosis, satisfaction, medication.
Full-Text [PDF 229 kb]   (526 Downloads)    
Type of Study: Original Article | Subject: Neurology
Received: 2021/08/28 | Accepted: 2022/05/18 | Published: 2023/01/21

XML     Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 14, Issue 1 (Winter 2023) Back to browse issues page